Health Condition 1: C749- Malignant neoplasm of unspecifiedpart of adrenal gland
Conditions
Interventions
Intervention1: nil: nil
Control Intervention1: nil: nil
Sponsors
Indian Pediatric Hematology Oncology Group INPHOG
Eligibility
Inclusion criteria
Inclusion criteria: 1. All newly diagnosed patients with confirmed low-risk and intermittent-risk neuroblastoma, seen at participating institutions are eligible for this study. 2. All patients and/or their parents or legal guardians must sign a written informed consent with age-appropriate child assent.
Exclusion criteria
Exclusion criteria: 1 Patients who are high risk i.e. they have tumors with MYCN amplification or have metastatic disease and are over 12 months of age or are 12-18 months of age with documented SCA, are excluded from this protocol. 2 Patients with ganglioneuroma are excluded. 3 Absent informed consent and age-appropriate assent 4 In the case of children who have received chemotherapy for LTS there is no documentation of the chemotherapy received or the child has received more than 2 cycles of chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year overall survival outcome for children with low risk and intermediate risk neuroblastomaTimepoint: 3year survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To implement a uniform risk stratification 2.To determine the progression free survival 3. To establish an INPHOG neuroblastoma surgical tumour boardTimepoint: 3 years | — |
Countries
India
Contacts
Public ContactDrYamini Krishnan
MVR Cancer centre and Research Institute.
Outcome results
None listed